Predictive values of clinical and pathological parameters for malignancy of gastrointestinal stromal tumors.

Gastrointestinal stromal tumors (GISTs) possess a wide spectrum of biological properties, from indolent to highly aggressive. In this study, we evaluated a set of clinical and pathological parameters for their predicative values for malignancy of GISTs by retrospective reviews of tumor specimens and their relevant medical records from 840 patients. All GIST cases were first assigned as malignant if they met any of the following criteria: gross spreads, including liver metastassis and/or peritoneal dissemination, microscopic spreads, including lymph node metastasis, infiltrations to vascular, fat, nerve and muscularis mucosal tissues, or relapse. The remaining cases were recorded as biological behavior uncertain. This initial assignment revealed a set of five morphological features to be associated with malignancy. They were: mitotic counts greater than 10 per 50HPFs (P<0.0001), muscularis propria infiltration (P<0.0001), coagulative necrosis (P<0.0001), perivascular growth pattern (P=0.005), and severe nuclear atypia (P=0.014). Therefore, a new classification system, including criteria of 2 gross spreads, 5 microscopic spreads, and 5 histopathological parameters was developed. All the GIST cases were re-classified into a group of 485 malignant tumors, and a group of 355 nonmalignant tumors. Patient follow-up data revealed 5-year disease-free and overall survival rates as high as 99.3% and 100% for the nonmalignant group, but low rates of 43.9% and 59.7% for the malignant group. These results demonstrated a correlation of the new classification with clinical outcomes. Therefore, this set of 12 parameters has predictive values for malignancy of GISTs, and is potentially useful in the grading of the tumors.

[1]  J. Lasota,et al.  Gastrointestinal stromal tumours. , 1998, Annales chirurgiae et gynaecologiae.

[2]  J. Fletcher,et al.  Gastrointestinal stromal tumors , 2010, Virchows Archiv.

[3]  S. Hirota,et al.  An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors , 2007, International Journal of Clinical Oncology.

[4]  Chien-Feng Li,et al.  A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. , 2007, Surgery.

[5]  S. Eccles,et al.  Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.

[6]  Y. Avni,et al.  The Cyclin-Dependent Kinase Inhibitor, p27kip1, Has No Correlation with the Malignant Potential of GIST , 2007, Digestion.

[7]  J. Royster AGAI technical review statements regarding GIST are troubling. , 2007, Gastroenterology.

[8]  Y. Ji,et al.  Schwannoma of the gastrointestinal tract: a clinicopathological, immunohistochemical and ultrastructural study of 33 cases , 2006, Histopathology.

[9]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Jejunum and Ileum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 906 Cases Before Imatinib With Long-term Follow-up , 2006, The American journal of surgical pathology.

[10]  Y. Oda,et al.  Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. , 2005, Human pathology.

[11]  B. Nilsson,et al.  Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.

[12]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up , 2005, The American journal of surgical pathology.

[13]  Huichang Yan,et al.  Prognostic Assessment of Gastrointestinal Stromal Tumor , 2003, American journal of clinical oncology.

[14]  Y. Nakanishi,et al.  Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients , 2003, Gastric Cancer.

[15]  S. Hirohashi,et al.  Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. , 2002, Human pathology.

[16]  J. Goldblum,et al.  Gastric Stromal Tumors: A Clinicopathologic Study of 77 Cases With Correlation of Features With Nonaggressive and Aggressive Clinical Behaviors , 2002, The American journal of surgical pathology.

[17]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[18]  W. El-Rifai,et al.  Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. , 2002, Human pathology.

[19]  L. Sobin,et al.  Gastrointestinal Stromal Tumors and Leiomyosarcomas in the Colon: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases , 2000, The American journal of surgical pathology.

[20]  L. Sobin,et al.  Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. , 2000, The American journal of surgical pathology.

[21]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[22]  J. Goldblum,et al.  Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases. , 1999, The American journal of surgical pathology.

[23]  J. Goldblum,et al.  Stromal tumors of the anorectum: a clinicopathologic study of 22 cases. , 1999, The American journal of surgical pathology.

[24]  J. Rodríguez-Peralto,et al.  Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. , 1997, Human pathology.

[25]  A. Ochiai,et al.  Reevaluation of prognostic factors in gastric leiomyosarcoma. , 1995, The American journal of gastroenterology.

[26]  M. Miettinen,et al.  Gastrointestinal stromal tumors--value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. , 1995, The American journal of surgical pathology.

[27]  S. Haque,et al.  Stromal neoplasms of the rectum and anal canal. , 1992, Human pathology.

[28]  M. Enjoji,et al.  A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors , 1992, Cancer.

[29]  P. Quirke,et al.  A Flow Cytometric, Clinical, and Histological Study of Stromal Neoplasms of the Gastrointestinal Tract , 1992, The American journal of surgical pathology.

[30]  C. Compton,et al.  Benign Smooth Muscle Tumors of the Gastrointestinal Tract: A 24‐Year Experience , 1990, Annals of surgery.

[31]  M. Miettinen,et al.  Gastrointestinal stromal tumors. An immunohistochemical study of cellular differentiation. , 1988, American journal of clinical pathology.

[32]  G. Parker,et al.  Gastrointestinal sarcomas. Analysis of prognostic factors. , 1987, Annals of surgery.

[33]  H. Evans Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years , 1985, Cancer.

[34]  R. Buxton Smooth muscle tumors of the gastrointestinal tract. , 1960, The American surgeon.

[35]  J. Goldblum,et al.  Stromal tumors of the duodenum. A histologic and immunohistochemical study of 20 cases. , 1995, The American journal of surgical pathology.

[36]  G. Farr,et al.  Myosarcomas of the stomach: Natural history, prognostic factors and management , 1982, Cancer.